<DOC>
	<DOCNO>NCT00207688</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety information infliximab patient participate infliximab clinical study ulcerative colitis .</brief_summary>
	<brief_title>A Long Term Safety Study Infliximab ( Remicade ) Ulcerative Colitis Patients</brief_title>
	<detailed_description>This long term , multicenter , international safety study evaluate target long-term safety information patient participate infliximab ( Remicade ) clinical study ulcerative colitis require long-term safety follow-up . All patient receive least one dose study drug ( infliximab placebo ) primary study ( C0168T37 , C0168T46 , C0168T72 ) eligible participate long-term safety follow-up study ( C0168T62 ) . Patients begin participation C0168T62 time last safety visit primary study follow 5 year . No study agent administer . Information death , serious infection , new malignancy ( include colorectal cancer ) new autoimmune diseases surgical procedure ( include colectomy ) hospitalization treatment ulcerative colitis collect . Information possible delayed allergic reaction ( possible fever , rash , fatigue , joint pain ) also collect patient receive infliximab end primary study . In addition , data dysplasia colon collect patient identify primary study high-risk colon cancer require per protocol undergo follow-up colonoscopy part long-term safety follow-up . All adverse event , include non-serious adverse event , also collect .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>All patient enrol three Phase 3 Janssensponsored ( C0168T37 , C0168T46 , C0168T72 ) infliximab clinical study ulcerative colitis require longterm safety followup Patients must receive least 1 dose study agent eligible participation study Patients refuse consent unwilling respond request longterm safety information within require timeframe exclude . In addition , patient participate study extension primary study eligible participation C0168T62 study study extension participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
	<keyword>Safety</keyword>
</DOC>